article
6 September 2016 | By Martina Fenske (Fraunhofer IME), Sheraz Gul (Fraunhofer IME)
Unforeseen efficacy and safety-related issues with drugs continue to be a major cause of their attrition, despite significant efforts that are expended to eliminate them prior to initiating clinical trials...